Company / Revenue
Lineage Cell Therapeutics, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$14.6M
FY2025
5-year range
$1.8M / $14.6M
FY2021-FY2025
Trend
+53.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has increased for 4 consecutive years, from $2M in FY2021 to $15M in FY2025.
Based on SEC 10-K filings.
$15M in FY2025 with a 5-year CAGR of +32.9%.
Improved from $9M to $15M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +49.7%
- 5-Year CAGR
- +32.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- Lineage Cell Therapeutics, Inc.'s revenue has grown for 4 consecutive years.
- 5-year CAGR of +32.9%, indicating consistent growth.
- In FY2025, revenue increased 53.2% year-over-year.
- Lowest revenue in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.6M | +53.2% |
| FY2024 | $9.5M | +6.2% |
| FY2023 | $8.9M | +106.1% |
| FY2022 | $4.3M | +137.7% |
| FY2021 | $1.8M | -48.1% |
| FY2020 | $3.5M | -29.5% |
| FY2019 | $5.0M | +44.2% |
| FY2018 | $3.5M | -50.9% |
| FY2017 | $7.0M | +34.2% |
| FY2016 | $5.2M | +18.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026